Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$14.48M+39043.24%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy T. Goodnow
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 130
- Beta
- 0.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.78
Financials
Revenue
$14.48M+39043.2%Net Income
$-36.70MEBITDA
$-34.56MFree Cash Flow
$-30.36MEPS (diluted)
$-0.63Shares Outstanding (diluted)
57.84M+1138.8%Operating Expenses
$44.55MCash & Debt
$142.66MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.26M | $-69.11M | $-1.66 |
| 2024 | $22.47M | $-78.62M | $-2.50 |
| 2023 | $22.39M | $-60.39M | $-2.20 |
| 2022 | $16.39M | $142.12M | $6.07 |
| 2021 | $13.68M | $-302.47M | $-14.40 |
| 2020 | $4.95M | $-175.17M | $-15.40 |
| 2019 | $21.30M | $-115.55M | $-12.20 |
| 2018 | $18.91M | $-93.97M | $-12.00 |
| 2017 | $6.37M | $-59.10M | $-10.20 |
| 2016 | $332.0K | $-43.93M | $-9.80 |
| 2015 | $38.0K | $-29.88M | $-6.60 |
| 2014 | $0.00 | $-18.89M | $-4.20 |
| 2013 | $17.0K | $-18.78M | $-5.00 |
Valuation
SENShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Positive
… Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.
View source ↗ - Newsglobenewswire.com·4d ago·Positive
Senseonics To Participate in Upcoming Institutional Investor Conferences GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.
View source ↗
Earnings
Wed, Nov 4(in 7 weeks)
Consensus estimate $-0.52 per share
Typical surprise -3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.63 vs $-0.61miss
- Thu, May 7$-0.71 vs $-0.69miss
- Mon, Mar 2$-0.46 vs $-0.43miss
- Wed, Nov 5$-0.43 vs $-0.33miss
- Wed, Aug 6$-0.40 vs $-0.40beat
- Thu, May 8$-0.40 vs $-0.40beat
Estimates and results for SENS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SENS officers and directors.
- Bought
- $737k
- Sold
- —
8 trades
0 trades
- Roeder Douglas Abought
- Roeder Douglas Abought
- Roeder Douglas Abought
- Goodnow Timothy Tbought
- Steven Edelmanbought
- Roeder Douglas Abought
- Sullivan Frederick T.bought
- Goodnow Timothy Tbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SENS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.